Publications

1. DeMarini D, Gwinn W, Watkins E, Reisfeld B, Chiu WA, Zeise L, et al. (2025). IARC workshop on the key characteristics of carcinogens: assessment of endpoints for evaluating mechanistic evidence of carcinogenic hazards. Environ Health Perspect. (forthcoming)
2. Berrington de González A, Masten SA, Bhatti P, Fortner RT, Peters S, Santonen T, et al. (2024). Advisory Group recommendations on priorities for the IARC Monographs. Lancet Oncol. 25(5):546–8. https://doi.org/10.1016/S1470-2045(24)00208-0 PMID:38621402
3. Middleton DRS, Wedekind R, Hall AL, Suonio E, DeBono NL, Vermeulen RCH, et al. (2024). Critical reviews of exposure assessment in carcinogenic hazard identification: the IARC Monographs experience. Occup Environ Med. 81(7):366–372. https://doi.org/10.1136/oemed-2023-109277 PMID:39033030
4. DeBono NL, Daniels RD, Beane Freeman LE, Graber JM, Hansen J, Teras LR, et al. (2023). Firefighting and cancer: a meta-analysis of cohort studies in the context of cancer hazard identification. Saf Health Work. 14(2):141–52. https://doi.org/10.1016/j.shaw.2023.02.003 PMID:37389311
5. M Filho A, Turner MC, Warnakulasuriya S, Richardson DB, Hosseini B, Kamangar F, et al. (2023). The carcinogenicity of opium consumption: a systematic review and meta-analysis. Eur J Epidemiol. 38(4):373–89. https://doi.org/10.1007/s10654-023-00969-7 PMID:36773182
6. Schubauer-Berigan MK (2023). Invited perspective: Good measure – assessing impact of cancer hazard identification on policies for cancer prevention. Environ Health Perspect. 131(12):121302. https://doi.org/10.1289/EHP14099 PMID:38088578
7. Turner MC, Cogliano V, Guyton K, Madia F, Straif K, Ward EM, et al. (2023). Research recommendations for selected IARC-classified agents: impact and lessons learned. Environ Health Perspect. 131(10):105001. https://doi.org/10.1289/EHP12547 PMID:37902675
8. Reisfeld B, de Conti A, El Ghissassi F, Benbrahim-Tallaa L, Gwinn W, Grosse Y, et al. (2022). kc-hits: a tool to aid in the evaluation and classification of chemical carcinogens. Bioinformatics. 38(10):2961–2. https://doi.org/10.1093/bioinformatics/btac189 PMID:35561175
9. Giesen C, Goldman-Levy G, Cree IA, Cierco Jimenez R, Machado A, Lokuhetty D (2024). WHO Classification of Tumours: moving towards the sixth edition. Histopathology. https://doi.org/10.1111/his.15325 PMID:39293942
10. Colling R, Indave I, Del Aguila J, Jimenez RC, Campbell F, Chechlińska M, et al. (2024). A new Hierarchy of Research Evidence for Tumor Pathology: a Delphi study to define levels of evidence in tumor pathology. Mod Pathol. 37(1):100357. https://doi.org/10.1016/j.modpat.2023.100357 PMID:37866639
11. Colling R, Indave I, Del Aguilla J, Cierco Jimenez R, Campbell F, Chechlinska M, et al. (2024). Moving forward on tumor pathology research reporting: a guide for pathologists from the World Health Organization Classification of Tumors Living Evidence Gap Map by Tumour Type Group. Mod Pathol. 37(7):100515. https://doi.org/10.1016/j.modpat.2024.100515 PMID:38763419
12. Shafique A, Gonzalez R, Pantanowitz L, Tan PH, Machado A, Cree IA, et al. (2024). A preliminary investigation into search and matching for tumor discrimination in World Health Organization breast taxonomy using deep networks. Mod Pathol. 37(2):100381. https://doi.org/10.1016/j.modpat.2023.100381 PMID:37939901
13. Cree IA (2023). The new WHO cytopathology reporting systems – extending the WHO classification of tumors. J Am Soc Cytopathol. 12(4):239–42. https://doi.org/10.1016/j.jasc.2023.04.004 PMID:37244847
14. Milman T, Grossniklaus HE, Goldman-Levy G, Kivelä TT, Coupland SE, White VA, et al.; WHO Classification of Tumours Editorial Board (2023). The 5th edition of the World Health Organization Classification of Tumours of the Eye and Orbit. Ocul Oncol Pathol. 9(3–4):71–95. https://doi.org/10.1159/000530730 PMID:37900189
15. Menon S, Moch H, Berney DM, Cree IA, Srigley JR, Tsuzuki T, et al. (2023). WHO 2022 classification of penile and scrotal cancers: updates and evolution. Histopathology. 82(4):508–20. https://doi.org/10.1111/his.14824 PMID:36221864
16. Rumgay H, Nethan ST, Shah R, Vignat J, Ayo-Yusuf O, Chaturvedi P, et al. (2024). Global burden of oral cancer in 2022 attributable to smokeless tobacco and areca nut consumption: a population attributable fraction analysis. Lancet Oncol. 25(11):1413–23. https://doi.org/10.1016/S1470-2045(24)00458-3 PMID:39393386
17. Sohi I, Rehm J, Saab M, Virmani L, Franklin A, Sánchez G, et al. (2024). Alcoholic beverage consumption and female breast cancer risk: a systematic review and meta-analysis of prospective cohort studies. Alcohol Clin Exp Res (Hoboken). 48(12):2222–41. https://doi.org/10.1111/acer.15493 PMID:39581746
18. Gapstur SM, Bouvard V, Nethan ST, Freudenheim JL, Abnet CC, English DR, et al. (2023). The IARC perspective on alcohol reduction or cessation and cancer risk. N Engl J Med. 389(26):2486–94. https://doi.org/10.1056/NEJMsr2306723 PMID:38157507
19. Bouvard V, Nethan ST, Singh D, Warnakulasuriya S, Mehrotra R, Chaturvedi AK, et al. (2022). IARC perspective on oral cancer prevention. N Engl J Med. 387(21):1999–2005. https://doi.org/10.1056/NEJMsr2210097 PMID:36378601
20. Bouvard V, Wentzensen N, Mackie A, Berkhof J, Brotherton J, Giorgi-Rossi P, et al. (2021). The IARC perspective on cervical cancer screening. N Engl J Med. 385(20):1908–18. https://doi.org/10.1056/NEJMsr2030640 PMID:34758259